Latest Investment News

WhiteHawk Limited reports an 8.6% revenue increase and a 26% reduction in net loss for H1 2025, alongside new US government contracts and a $1.56 million capital raise.

Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.

Atlas Pearls reported increased pearl harvest and sales volumes for FY25, driving revenue growth to $44.3 million, though profits declined compared to the previous year. The company declared a fully franked final dividend, underscoring its solid financial footing.

Cettire Limited reported FY25 results showing stable sales revenue and a breakeven adjusted EBITDA despite a challenging luxury goods market. The company’s strategic focus on profitability, supply chain expansion, and emerging markets diversification underpins its resilience.

Cettire Limited reported stable revenue for FY25 despite a challenging luxury market, but profitability sharply declined due to increased promotional activity and softer demand.

Echelon Resources reports a robust 34% revenue increase and 26% production growth for FY2025, driven by expanded stakes and drilling success at the Mereenie field. The company balances strong cash flow with strategic reinvestment and a modest dividend.

Echelon Resources Limited reported a robust financial year ending June 2025, driven by strategic asset acquisitions and strong commodity prices, delivering a 34% revenue increase and a near 20-fold jump in net profit after tax.

Atlas Pearls Ltd reported a 6% revenue increase to $44.3 million in FY25 despite a 30% drop in net profit, unveiling a strategic roadmap targeting up to 50% production growth by FY30 alongside a fully franked dividend.

Civmec Limited posted solid FY25 results with $810.6 million revenue and a strategic acquisition boosting its naval shipbuilding footprint. The company’s $1.25 billion order book and focus on low-carbon sectors set the stage for growth.

Civmec Limited reported solid FY2025 financials with revenue surpassing A$810 million and a strengthened order book of A$1.25 billion, underpinned by its strategic acquisition of Luerssen Australia.

Experience Co Limited reports a robust FY25 with revenue growth and a significant jump in earnings, driven by a tourism rebound in Australia and New Zealand.

Cynata Therapeutics reported a $9.39 million net loss for FY2025, slightly improved from the prior year, while progressing multiple clinical trials with key results expected in 2026. The company maintains a solid cash position and funding runway through mid-2026, supported by recent capital raises and an equity subscription agreement.